Study of efficacy of Yokuinin in cervical intraepithelial neoplasma.

Study of efficacy of Yokuinin in cervical intraepithelial neoplasma. - Study of efficacy of Yokuinin in cervical intraepithelial neoplasma.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014118

Enrollment

Registered

2014-05-30

Start date

2013-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients diagnosed with CIN1, CIN2, CIN3 in cervical cytology.

Interventions

Yokuinin

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients diagnosed with CIN1, CIN2, CIN3 in cervical cytology. 1. Patient who are not pregnant or breastfeeding. 2. Patients aged 20 years old and older and 65 years old and under. 3. Patient who is CIN-positive in HPV test of HC-II. 4. Patients who will be able to obtain written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who take the steroid and/or the immunosuppressant, or with severe disease. 2. Patients who were judged to be inappropriate for the study by the investigator.

Design outcomes

Primary

Measure	Time frame
1. Cervical cytology 2. Examination liquefaction specimen cell (LBC) 3. HPV-genotyping test	—

Countries

Japan

Contacts

Public ContactToshiyuki Sasagawa

Kanazawa Medical University Obstetrics and Gynecology

tsasa@kanazawa-med.ac.jp076-286-2211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026